These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
142 related articles for article (PubMed ID: 29317918)
1. Awareness of the implementation of the Falsified Medicines Directive among pharmaceutical companies' professionals in the European Economic Area. WŁodarczak U; Swieczkowski D; Religioni U; Jaguszewski M; Krysinski J; Merks P Pharm Pract (Granada); 2017; 15(4):1031. PubMed ID: 29317918 [TBL] [Abstract][Full Text] [Related]
2. Fighting trafficking of falsified and substandard medicinal products in Russia. Fayzrakhmanov NF Int J Risk Saf Med; 2015; 27 Suppl 1():S37-40. PubMed ID: 26639702 [TBL] [Abstract][Full Text] [Related]
3. The European Falsified Medicines Directive in Poland: background, implementation and potential recommendations for pharmacists. Merks P; Swieczkowski D; Byliniak M; Drozd M; Krupa K; Jaguszewski M; Brindley DA; Naughton BD Eur J Hosp Pharm; 2018 Jan; 25(1):10-15. PubMed ID: 29445453 [TBL] [Abstract][Full Text] [Related]
4. Evaluation of community pharmacists' readiness to implement the Falsified Medicines Directive (Directive 2011/62/EC): an English cross-sectional survey with geospatial analysis. Barrett R BMJ Open; 2020 Jan; 10(1):e033405. PubMed ID: 31924640 [TBL] [Abstract][Full Text] [Related]
5. Pharmacists' views on the impact of the Falsified Medicines Directive on community pharmacies: A cross-sectional survey. Dalton K; Connery C; Murphy KD; O'Neill D Explor Res Clin Soc Pharm; 2022 Mar; 5():100127. PubMed ID: 35478525 [TBL] [Abstract][Full Text] [Related]
6. Legal aspects of counteracting the trafficking of falsified medicines in the european union. Pashkov V; Soloviov A; Olefir A Wiad Lek; 2017; 70(4):843-849. PubMed ID: 29064815 [TBL] [Abstract][Full Text] [Related]
7. Falsified Medicines Directive in a Secondary Care Environment-Impact on Supply Chain. Merks P; Religioni U; Pinto de Castro N; Augustynowicz A; Plagens-Rotman K; Brindley D; Kowalczuk A; Kaźmierczak J; Neumann-Podczaska A; Blicharska E; Sola KF; Hug MJ; Gajewski K; Piątkiewicz P Int J Environ Res Public Health; 2022 Mar; 19(6):. PubMed ID: 35328963 [TBL] [Abstract][Full Text] [Related]
8. Hospital Audit as a Useful Tool in the Process of Introducing Falsified Medicines Directive (FMD) into Hospital Pharmacy Settings-A Pilot Study. Religioni U; Swieczkowski D; Gawrońska A; Kowalczuk A; Drozd M; Zerhau M; Smoliński D; Radomiński S; Cwalina N; Brindley D; Jaguszewski MJ; Merks P Pharmacy (Basel); 2017 Nov; 5(4):. PubMed ID: 29120385 [TBL] [Abstract][Full Text] [Related]
9. The impact of global falsified medicines regulation on healthcare stakeholders in the legitimate pharmaceutical supply chain: a systematic review. Melia E; English A; Naughton BD Front Med (Lausanne); 2024; 11():1429872. PubMed ID: 39091292 [TBL] [Abstract][Full Text] [Related]
10. Pharmaceutical Regulatory Framework in Ethiopia: A Critical Evaluation of Its Legal Basis and Implementation. Suleman S; Woliyi A; Woldemichael K; Tushune K; Duchateau L; Degroote A; Vancauwenberghe R; Bracke N; De Spiegeleer B Ethiop J Health Sci; 2016 May; 26(3):259-76. PubMed ID: 27358547 [TBL] [Abstract][Full Text] [Related]
11. [securPharm e. V. - a protective shield against falsified medicines]. Bergen M; Hoferichter R Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz; 2017 Nov; 60(11):1255-1260. PubMed ID: 28929207 [TBL] [Abstract][Full Text] [Related]
13. Fighting falsified medicines with paperwork - a historic review of Danish legislation governing distribution of medicines. Borup R; Kaae S; Minssen T; Traulsen J J Pharm Policy Pract; 2016; 9():30. PubMed ID: 27713830 [TBL] [Abstract][Full Text] [Related]
14. Falsified Drugs in the Opinion of Patients Diagnosed with Cardiovascular Diseases-Nationwide and Cross-Sectional Study on the Example of EU-Member Country. Świeczkowski D; Zdanowski S; Merks P; Jaguszewski M Int J Environ Res Public Health; 2021 Apr; 18(7):. PubMed ID: 33917444 [TBL] [Abstract][Full Text] [Related]
15. Point-of-Care Anti-Counterfeit Medicines Technologies: Awareness and Utilization among Medical Practitioners in Eastern Nigeria. Iloh GU; Akodu BA; Emeka EA; Obi IV West Afr J Med; 2021 Nov; Vol. 38(11):1029-1035. PubMed ID: 34918894 [TBL] [Abstract][Full Text] [Related]
16. A nationwide web-based survey of a sample of Italian community pharmacists' perceptions and opinions about online sales of medicines and falsified drugs. Lombardo S; Marino F; Cosentino M Pharm Pract (Granada); 2019; 17(4):1593. PubMed ID: 31897254 [TBL] [Abstract][Full Text] [Related]
17. The Epidemic of Substandard and Falsified Medications in Iraq: Evaluating the Effectiveness of National Pharmacovigilance Alerts to Community Pharmacies. Al-Jumaili AA; Younus MM; Saleh MZ Pharmaceut Med; 2021 May; 35(3):169-186. PubMed ID: 33864206 [TBL] [Abstract][Full Text] [Related]
19. Regulatory Capture in Pharmaceutical Policy Making: The Case of National Medicine Agencies Related to the EU Falsified Medicines Directive. Borup R; Traulsen JM; Kaae S Pharmaceut Med; 2019 Jun; 33(3):199-207. PubMed ID: 31933284 [TBL] [Abstract][Full Text] [Related]
20. [Falsified pharmaceutical products : Legislative measures in the European Union and in Germany]. Sträter B Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz; 2017 Nov; 60(11):1188-1195. PubMed ID: 28929177 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]